Bipolar Disorder Clinical Trials in Philadelphia

Showing 81-84 of 84 trials

The Assessment of a Weight-Gain Agent for the Treatment of Olanzapine-Associated Anti-Obesity Agent in Patients With Schizophrenia, Schizophreniform Disorder, Schizoaffective Disorder, and Bipolar I Disorder

NCT00044187

Olanzapine is currently marketed for the treatment of schizophrenia and acute manic episodes with bipolar 1 disorder. This Anti-obesity Agent is currently marketed for the management of obesity. In this study, the Anti-obesity Agent is being tested to see if it can treat weight gain that may be associated with taking olanzapine. The purposes of this study are to determine the safety of olanzapine when given in combination with the Anti-obesity Agent and any side effects that might be associated with it and whether weight-gain agent can help treat weight gain that may be associated with taking olanzapine.

SchizophreniaPsychotic DisordersBipolar Disorder

Eli Lilly and Company130 participantsStarted Apr 2001

El Centro, California, United States • Jacksonville, Florida, United States • Miami, Florida, United States +13 more locations

COMPLETEDPhase 338 miles

Triiodothyronine (T3) Supplementation in the Treatment of Bipolar and Unipolar Depression.

NCT00158990

The purpose of this project is to determine whether concurrent treatment of patients with major depression (unipolar or bipolar) with triiodothyronine (T3) and sertraline, will lead to a stronger and/or more rapid antidepressant effect than treatment with sertraline alone.

Major DepressionBipolar DisorderUnipolar Depression

Hadassah Medical Organization220 participantsStarted Oct 2002

Princeton, New Jersey, United States • Jerusalem, Israel

TERMINATEDPhase 481 miles

Depakote Monotherapy, Olanzapine Monotherapy, and Combination Therapy of Depakote Plus Olanzapine in Stable Subjects During the Maintenance Phase of Bipolar Illness

NCT00071253

The purpose of this study is to assess the efficacy and safety of continued combination therapy using Depakote plus olanzapine, vs. Depakote monotherapy and olanzapine monotherapy in stable subjects during the maintenance phase of bipolar illness.

Bipolar Disorder

Abbott180 participantsStarted Jul 2003

Anaheim, California, United States • Chula Vista, California, United States • Fort Meyers, Florida, United States +12 more locations

The Assessment of a Weight-Gain Agent for the Treatment of Olanzapine-Associated Anti-Obesity Agent in Patients With Schizophrenia, Schizophreniform Disorder, Schizoaffective Disorder, and Bipolar I Disorder

Triiodothyronine (T3) Supplementation in the Treatment of Bipolar and Unipolar Depression.

Depakote Monotherapy, Olanzapine Monotherapy, and Combination Therapy of Depakote Plus Olanzapine in Stable Subjects During the Maintenance Phase of Bipolar Illness

Bipolar Disorder Trials in Other Cities

Bipolar Depression Study: Bipolar Depression Assessment Study on Treatment Response

Other Conditions in Philadelphia